Q2 FY27 revenue rises 28%, consolidated profit turns positive but standalone profit falls

Revenue Growth 20pctPat NegativeEbitda Margin ExpansionResults RestatedRelated Party TransactionsResults View source PDF Explain this filing

PPLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+15.4%Reaction day

₹199.75

prior close

₹214.10

announcement price

After-mkt

timing

Nifty Smallcap 250market+0.3%+15.1% vs market

Pharmaceuticals peers, median of 170sector+0.6%+14.9% vs sector

On the reaction day the stock moved 15.1 pts more than Nifty Smallcap 250 and 14.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.8

10m

+3.9

15m

+2.8

30m

+4.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+15.4+0.3+15.1+0.6+14.9

Next day

+15.5+1.0+14.5+1.1+14.4

+19.0pendingpending-0.3+19.3

—————

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 consolidated revenue rose 28% to Rs2,617.06 crore from Rs2,043.72 crore. Profit after tax swung to Rs5.03 crore from a Rs99.22 crore loss. For six months, revenue rose 23% to Rs4,886.98 crore, but net loss narrowed to Rs64.35 crore from Rs180.92 crore. Standalone Q2 profit after tax fell to Rs170.74 crore from Rs196.33 crore. Yapan Bio stake rose to 74% for Rs76.09 crore. Standalone net related-party loans were Rs227.10 crore.

Likely market impact

Revenue growth and a profit turnaround help, but the half-year loss, lower standalone profit and related-party loans make the outlook mixed.